Research Program
Value of Life Sciences Innovation
Biomedical advances are at the front lines of transforming healthcare through innovations that benefit countless people. The Value of Life Sciences Innovation (VLSI) program exemplifies the Schaeffer Center’s focus on evidence-based analyses that encourage breakthroughs while developing pricing and reimbursement strategies to help ensure that patients receive the therapies they need.
Program Leadership
-
Karen Van Nuys, PhD
Executive Director, Value of Life Sciences Innovation, USC Schaeffer Center
-
Dana Goldman, PhD
Director, USC Schaeffer Institute
Co-Director, USC Schaeffer Center
University Professor of Public Policy, Pharmacy, and Economics, USC
-
Robert D. Reischauer, PhD
Nonresident Senior Fellow, USC Schaeffer Center
Distinguished Fellow and President Emeritus, The Urban Institute
The Price of Insulin
This animation explains research by Schaeffer Center experts that offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin. The video breaks down the players in the distribution chain as well as how the share of profits from insulin changed between 2014 and 2018.
Read Full StoryFeatured White Papers
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
Minimally invasive technologies are capacity-conserving technologies that could reduce burdens on healthcare providers and hospitals while also shielding patients from unnecessary in-hospital exposure to pathogens.
Health Technology Assessment in the U.S. – A Vision for the Future
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Schaeffer Solutions
Through sophisticated and rigorous analysis of drug costs, the Schaeffer Center created an evidence-based playbook for federal and state policymakers to tackle distortions in the drug distribution system.
Read Full Story
